Clinical Trial Update: Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on the PET-Stop trial uses biomarkers to guide safe discontinuation of immunotherapy in patients with unresectable stage III/IV …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING